Moreover, industry players are focusing on research and development of new tests for Lyme disease diagnosis and this is expected to aid in growth of the Lyme disease diagnostics market. For instance, in 2017, IGeneX Inc.—a Clinical Laboratory Improvement Amendments (CLIA) and New York-approved Reference Laboratory, specializing in testing for tick-borne diseases— launched three new tests that are more comprehensive and specific for assisting in diagnosis of tick-borne relapsing fever and Lyme disease. However, lack of awareness about the disease and inefficiency in Lyme disease testing significantly affects the market growth. Several individuals with Lyme-like symptoms are wrongly diagnosed, owing to existing serological tests that cannot identify antibodies of all the different strains of B. burgdorferi. Therefore, demand for better diagnostic tests for the disease is increasing. Since the symptoms of tick-borne relapsing fever and Lyme are similar, development of more accurate test is required for proper diagnosis.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients